Advaxis Announces Closing of Public Offering of Common Stock and Warrants
October 22 2013 - 11:46AM
Business Wire
Advaxis, Inc., (NASDAQ: ADXS, ADXSW), a leader in
developing the next generation of immunotherapies for cancer and
infectious diseases, today announced it has closed its public
offering of 6,612,500 shares of common stock, and warrants to
purchase up to an aggregate of 3,306,250 shares of its common
stock, including 862,500 shares and warrants to purchase 431,250
shares that were offered and sold by Advaxis, Inc. pursuant to the
full exercise of the underwriters’ over-allotment option, at a
price to the public of $4.00 per share and $0.001 per warrant. The
warrants have a per share exercise price of $5.00, 125% of the
public offering price of the common stock, are exercisable
immediately, and expire five years from the date of issuance. Total
gross proceeds from the offering were approximately $26,500,000,
before deducting underwriting discounts and commissions and other
offering expenses payable by Advaxis, Inc.
Aegis Capital Corp. acted as sole book-running manager for the
offering.
This offering was made only by means of a prospectus. Copies of
the prospectus relating to the offering may be obtained by
contacting Aegis Capital Corp., Prospectus Department, 810 Seventh
Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010,
e-mail: prospectus@aegiscap.com.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission
(“SEC”) on October 16, 2013 and an abbreviated registration
statement relating to these securities was effective upon filing
with the SEC on October 16, 2013. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the
next generation of immunotherapies for cancer and infectious
diseases. Advaxis immunotherapies are based on a novel platform
technology using live, attenuated bacteria that are bio-engineered
to secrete an antigen/adjuvant fusion protein(s) that is designed
to redirect the powerful immune response all human beings have to
the bacterium to the cancer itself.
ADXS-HPV is currently being evaluated in four clinical trials
for human papillomavirus (HPV)-associated cancers:
recurrent/refractory cervical cancer (India), locally advanced
cervical cancer (GOG/NCI U.S. study, Clinical Trials.gov Identifier
NCT01266460), head & neck cancer (CRUK study, Clinical
Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study,
Clinical Trials.gov Identifier NCT01671488). Advaxis has over 15
distinct immunotherapies in various stages of development,
developed directly by Advaxis and through strategic collaborations
with recognized centers of excellence such as: the National Cancer
Institute, Cancer Research – UK, the University of Pennsylvania,
the Georgia Regents University Cancer Center, and others.
For more information please visit: www.advaxis.com
Advaxis, Inc.Diana Moore, 609-452-9814Director, Investor
Relationsand Business Developmentdmoore@advaxis.comorJenene Thomas
Communications, LLCJenene Thomas, 908-938-1475Investor Relations
and CorporateCommunications Advisorthomasjenene@gmail.com
Advaxis - Warrants (delisted) (NASDAQ:ADXSW)
Historical Stock Chart
From Nov 2024 to Dec 2024
Advaxis - Warrants (delisted) (NASDAQ:ADXSW)
Historical Stock Chart
From Dec 2023 to Dec 2024
